Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anika Therapeutics, Inc.ANIK · Entity 6005 | SVP, Chief Operations Officer | March 14, 2025 | March 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anika Therapeutics, Inc.
Report date March 14, 2025 · Filed March 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,654 |
Ending reported balance
After 2025-03-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-03-17 · Exercise / conversion · Acquired 3,637 · Balance 21,722 F1: Reflects the first vesting installment of RSUs granted on March 15, 2024, which the Company elected to settle in shares. Row 2 · 2025-03-17 · Tax withholding · Disposed 1,068 · Balance 20,654 F2: Reflects an aggregate of 1,068 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 15, 2025. F3: Reflects the closing price of ANIK common stock on March 14, 2025, the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 20,761 |
Reported balance
After 2025-03-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-03-14 · Grant · Acquired 20,761 · Balance 20,761 F4: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 14, 2026. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 4,650 |
Reported balance
After 2025-03-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-03-14 · Grant · Acquired 4,650 · Balance 4,650 F5: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on the vest date. The 4,650 RSUs represent the Target number of shares that may be earned in conjunction with certain market metrics prescribed under the terms of the performance-based phantom RSU award. The award shall cliff vest on the 3rd anniversary of the grant date, subject to the Compensation Committee's determination of achievement of the award prior to the vest date. The number of shares earned and subject to vest, as determined by the Compensation Committee, may be in a range from Threshold (50% of Target) to Maximum (200% of Target). No shares shall vest for achievement under Threshold. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 7,275 |
Reported balance
After 2025-03-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-03-17 · Exercise / conversion · Disposed 3,637 · Balance 7,275 F6: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the first vesting installment of RSUs granted on March 15, 2024, which the Company elected to settle in shares.
F2: Reflects an aggregate of 1,068 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 15, 2025.
F3: Reflects the closing price of ANIK common stock on March 14, 2025, the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations.
F4: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 14, 2026.
F5: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on the vest date. The 4,650 RSUs represent the Target number of shares that may be earned in conjunction with certain market metrics prescribed under the terms of the performance-based phantom RSU award. The award shall cliff vest on the 3rd anniversary of the grant date, subject to the Compensation Committee's determination of achievement of the award prior to the vest date. The number of shares earned and subject to vest, as determined by the Compensation Committee, may be in a range from Threshold (50% of Target) to Maximum (200% of Target). No shares shall vest for achievement under Threshold.
F6: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2025 Filed Mar 18, 2025 21:16 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 3,637 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-001534 · ownership.xml · derivative · entry 5 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,275 Underlying: Common Stock · 3,637 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025. F6 · derivative.expiration_date: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 21:16 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 1,068 | $15.91 | $16,991.88 |
DisclosureSEC source: 0001171843-25-001534 · ownership.xml · nonDerivative · entry 2 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,654 F2 · shares: Reflects an aggregate of 1,068 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 15, 2025. F3 · price: Reflects the closing price of ANIK common stock on March 14, 2025, the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 21:16 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 3,637 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-001534 · ownership.xml · nonDerivative · entry 1 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the first vesting installment of RSUs granted on March 15, 2024, which the Company elected to settle in shares. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 21:16 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 4,650 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-001534 · ownership.xml · derivative · entry 4 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,650 Underlying: Common Stock · 4,650 shares Expires not disclosed F5 · derivative.exercise_date: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on the vest date. The 4,650 RSUs represent the Target number of shares that may be earned in conjunction with certain market metrics prescribed under the terms of the performance-based phantom RSU award. The award shall cliff vest on the 3rd anniversary of the grant date, subject to the Compensation Committee's determination of achievement of the award prior to the vest date. The number of shares earned and subject to vest, as determined by the Compensation Committee, may be in a range from Threshold (50% of Target) to Maximum (200% of Target). No shares shall vest for achievement under Threshold. F5 · derivative.expiration_date: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on the vest date. The 4,650 RSUs represent the Target number of shares that may be earned in conjunction with certain market metrics prescribed under the terms of the performance-based phantom RSU award. The award shall cliff vest on the 3rd anniversary of the grant date, subject to the Compensation Committee's determination of achievement of the award prior to the vest date. The number of shares earned and subject to vest, as determined by the Compensation Committee, may be in a range from Threshold (50% of Target) to Maximum (200% of Target). No shares shall vest for achievement under Threshold. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 21:16 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 20,761 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-001534 · ownership.xml · derivative · entry 3 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,761 Underlying: Common Stock · 20,761 shares Expires not disclosed F4 · derivative.exercise_date: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 14, 2026. F4 · derivative.expiration_date: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 14, 2026. Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 21:19 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 2,561 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-001470 · ownership.xml · derivative · entry 3 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,561 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023. F4 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023. Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 21:19 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 752 | $16.79 | $12,626.08 |
DisclosureSEC source: 0001171843-25-001470 · ownership.xml · nonDerivative · entry 2 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,085 F2 · shares: Reflects an aggregate of 752 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 11, 2025. F3 · price: Reflects the closing price of ANIK common stock on March 11, 2025, the trading day to which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 21:19 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 2,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-001470 · ownership.xml · nonDerivative · entry 1 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the third and final vesting installment of RSUs granted on March 11, 2022. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 21:18 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 3,296 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-001406 · ownership.xml · derivative · entry 3 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,295 Underlying: Common Stock · 3,296 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024. F5 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 21:18 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 959 | $16.62 | $15,938.58 |
DisclosureSEC source: 0001171843-25-001406 · ownership.xml · nonDerivative · entry 2 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,276 F3 · shares: Reflects an aggregate of 959 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2025. F4 · price: Reflects the closing price of ANIK common stock on March 7, 2025, the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 21:18 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 3,296 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-001406 · ownership.xml · nonDerivative · entry 1 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the second vesting installment of RSUs granted on March 9, 2023. F2 · balance_after: Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 460 shares purchased on November 14, 2024. Read SEC document |
| October 01, 2024 Filed Oct 4, 2024 20:06 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 2,491 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-005510 · ownership.xml · derivative · entry 3 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,491 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning October 1, 2022. F5 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning October 1, 2022. Read SEC document |
| October 01, 2024 Filed Oct 4, 2024 20:06 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 732 | $24.27 | $17,765.64 |
DisclosureSEC source: 0001171843-24-005510 · ownership.xml · nonDerivative · entry 2 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,479 F3 · shares: Reflects an aggregate of 732 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on October 1, 2024. F4 · price: Reflects the closing price of ANIK common stock on October 1, 2024, the trading day on which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| October 01, 2024 Filed Oct 4, 2024 20:06 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 2,491 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-005510 · ownership.xml · nonDerivative · entry 1 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the third and final vesting installment of RSUs granted on October 1, 2021. F2 · balance_after: Includes 634 shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan on May 14, 2024. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 21:17 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 26,442 | $0.00 Strike: $27.98 | $0.00 |
DisclosureSEC source: 0001171843-24-001459 · ownership.xml · derivative · entry 2 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,442 Underlying: Common Stock · 26,442 shares Expires 2034-03-11 F2 · derivative.exercise_price: Represents a 10% premium above the closing price of Anika's common stock on the date of grant. F3 · derivative.exercise_date: The premium priced stock options vest in three equal annual installments beginning on March 15, 2025. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 21:17 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 10,912 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-001459 · ownership.xml · derivative · entry 1 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,912 Underlying: Common Stock · 10,912 shares Expires not disclosed F1 · derivative.exercise_date: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025. F1 · derivative.expiration_date: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:02 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 2,561 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-001305 · ownership.xml · derivative · entry 6 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,561 Underlying: Common Stock · 2,561 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023. F10 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:02 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 3,295 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-001305 · ownership.xml · derivative · entry 5 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,591 Underlying: Common Stock · 3,295 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024. F9 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:02 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 752 | $25.79 | $19,394.08 |
DisclosureSEC source: 0001171843-24-001305 · ownership.xml · nonDerivative · entry 4 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,086 F7 · shares: Reflects an aggregate of 752 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 11, 2024. F8 · price: Reflects the closing price of ANIK common stock on March 11, 2024, the trading day on which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:02 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 2,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-001305 · ownership.xml · nonDerivative · entry 3 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: Reflects the second vesting installment of RSUs granted on March 11, 2022. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:02 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 968 | $25.42 | $24,606.56 |
DisclosureSEC source: 0001171843-24-001305 · ownership.xml · nonDerivative · entry 2 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,277 F4 · shares: Reflects an aggregate of 968 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2024. F5 · price: Reflects the closing price of ANIK common stock on March 8, 2024, the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:02 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 3,295 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-001305 · ownership.xml · nonDerivative · entry 1 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the first vesting installment of RSUs granted on March 9, 2023. F2 · balance_after: Reflects the corrected Amount of Shares Beneficially Owned under Table I, Column 2 as reported in Form 3/A filed by the Reporting Person on January 12, 2024. F3 · balance_after: Includes 414 shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan on November 14, 2023. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:31 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 2,491 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-006018 · ownership.xml · derivative · entry 3 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,491 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning October 1, 2022. F4 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning October 1, 2022. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:31 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 732 | $18.63 | $13,637.16 |
DisclosureSEC source: 0001171843-23-006018 · ownership.xml · nonDerivative · entry 2 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,052 F2 · shares: Reflects an aggregate of 732 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on October 1, 2023. F3 · price: Reflects the closing price of ANIK common stock on September 29, 2023, the trading day on which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:31 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 2,491 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-006018 · ownership.xml · nonDerivative · entry 1 Nunes Anne · CIK 0001982862 · SVP, Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the second vesting installment of Restricted Stock Units (RSUs) granted on October 1, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.